Experimental drug CS18 may overcome cancer treatment resistance, Baylor study finds
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Baylor College of Medicine researchers report in Science Advances that CS18, an experimental drug targeting TopBP1, a regulator of multiple cancer pathways, may help tumors that have grown resistant to therapy. Early evidence shows it strengthened existing treatments, restored sensitivity in resistant lung cancer cells, and slowed tumor growth in animal models.
Continue in the app — vote & join in ➔Source: ScienceDaily · via ahirlevel.hu